School of Medicine
Showing 541-560 of 864 Results
-
Chloe Nobuhara
Masters Student in Epidemiology and Clinical Research, admitted Autumn 2025
BioDr. Chloe Nobuhara is a Stanford general surgery resident and AI researcher dedicated to upholding patient safety standards while pursing aggressive surgical innovation. Currently on a two-year professional development track during residency, her research explores the intersection of AI and surgical practice. She has collaborated with the Medical AI and Computer Vision (MARVL) Lab to use computer vision and vision language models for performance assessment, worked with the Operating Room Black Box technologies for ambient intelligence and automated documentation, and most recently is helping to organize a foreign body identification challenge for MICCAI.
Dr. Nobuhara holds an MD from Duke University and an undergraduate degree from Northeastern University. Originally hailing from Honolulu, Hawaii, she brings a global perspective to her work, having flown over 100,000 miles (4x around the globe) for speaking engagements and conferences during her research time. -
Peter Nonso Nwokoye
MD Student with Scholarly Concentration in Bioengineering, expected graduation Spring 2027
BioPeter Nonso Nwokoye was born and raised in Nigeria and graduated summa cum laude with dual Bachelor of Science degrees in Chemistry and Biology from Barry University. During his undergraduate studies, he worked on the synthesis of selective muscarinic receptor agonists and antagonists. In 2021, he was awarded the prestigious Gates Cambridge Scholarship to study at King's College, University of Cambridge. There, under the mentorship of Professor Anthony Davenport, he researched the expression and signaling of the apelin receptor and its endogenous agonists, Elabela and Apelin, in glioblastoma stem cells. This experience sparked his interest in developing novel methods to deorphanize orphan Class A GPCRs. After several months of intensive computational research, Peter developed a complex, multi-layered bioinformatic tool that he has used to identify likely endogenous ligands of orphan GPCRs, focusing on peptide ligands found in annotated uncharacterized open reading frames in the human genome. In his free time, he enjoys soccer, running, meditating, and teaching. Peter is excited about pursuing a career as a physician-scientist.
-
Marcus Oehlrich, PhD
Masters Student in Biomedical Data Science, admitted Autumn 2025
BioI am a Professor of Finance, Accounting, and Taxation at accadis University of Applied Sciences in Bad Homburg, Germany, and I advise on startups, business valuation, and corporate finance. My consulting projects range from small startups in biotechnology and M&A transactions in the pharmaceutical and biotech sectors to the preparation of the business plan for the IPO of an international music and movie production group.
During my business studies, I became interested in law and medicine (especially cancer research), which is why I continued my education in these fields (including a Master of Science in Pharmaceutical Medicine, a Certificate in Pharmaceutical Law, and an MPH at Harvard T.H. Chan School of Public Health). Subsequently, I have started the M.S. in Biomedical Data Science at the Department of Biomedical Data Science at Stanford University School of Medicine.
I also had the privilege of serving as the CEO of the Institute for German, European, and International Medical Law, Health Law, and Bioethics of the Universities of Heidelberg and Mannheim (IMGB) from 2005 to 2011. At accadis University of Applied Sciences, I am Head of the Health Care Management Research Group and responsible for the Master of Arts in International Health Care Management. From 2010 to 2020, I served as the Honorary Consul of the Republic of San Marino in Frankfurt, Germany.
Most of my publications (12 books and more than 70 articles) are related to business topics. However, I also authored three books on cancer "Internetkompass Krebs [Internet compass cancer]" (Springer 2001), "Recombinant humanized monoclonal antibody Trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2/neu proto-oncogene: A systematic review" (dissertation.de 2003) and "Krebs vorbeugen und bekämpfen [Preventing and combating cancer: All about prevention, early detection, therapy]" (Reader's Digest 2012). The latter was translated into Polish, Czech, Croatian, Slovenian, and Hungarian.
